Publication date: Sep 10, 2025
Between November 2024 and April 2025, the Canadian Sentinel Practitioner Surveillance Network assessed KP.2 vaccine effectiveness against outpatient COVID-19 by test-negative design. Vaccination protected best during the first two months, reducing risk by two-thirds among vaccinated versus unvaccinated individuals, declining by 3-4 months, and reducing the risk overall by half.
| Concepts | Keywords |
|---|---|
| Canadian | Canada |
| Influenza | Covid |
| Microbiology | Effectiveness |
| S1473309925003809 | Estimates |
| Https | |
| Kp | |
| Medrxiv | |
| Preprint | |
| Sars | |
| Season | |
| September | |
| Vaccination | |
| Vaccine | |
| Vaccines | |
| Weeks |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| pathway | KEGG | Coronavirus disease |
| disease | MESH | emergency |
| disease | MESH | influenza |
| disease | MESH | Infectious Diseases |
| drug | DRUGBANK | Fosfomycin |
| disease | MESH | death |
Download Document
(Visited 4 times, 1 visits today)